Composition and release form
| Film-coated tablets | 1 table |
| mallow ( Hibiscus abelmoschus ) | 10 mg |
| Powders: | |
| Withania somnifera roots | 65 mg |
| roots of beautiful argyreia ( Argyreia speciosa ) | 32 mg |
| velvet bean seeds ( Mucuna pruriens ) | 32 mg |
| columns with stigmas of saffron ( Crocus sativus ) | 25 mg |
| Chillibuja seeds (neutralized) ( Strychnos nux-vomica ) | 16 mg |
| rhizomes of male orchis ( Orchis mascula ) | 16 mg |
| roots of the medicinal saliva ( Anacyclus pyrethrum ) | 16 mg |
| whole plant of Sida cordifolia | 16 mg |
| bark of the Malabar bombax ( Bombax malabaricum ) | 16 mg |
| black pepper fruit ( Piper nigrum ) | 5 mg |
| mummy purified ( Asphaltum purified ( Shilajeet ) | 32 mg |
| mineral ( Trivang ) | 32 mg |
| Makardhwaj | 16 mg |
| steamed extracts from a mixture of the following plant materials: whole plant of Sida cordifolia , roots of asparagus racemosus , tubers of sweet potato ( Ipomoea digitata ), leaves of betel pepper ( Piper betle ), roots of Withania somnifera , Tribulus terrestris fruits Tinospora cordifolia stems speciosa roots, arabica fruits Dashamoola root mixture | |
| excipients: magnesium stearate; MCC; sodium carboxymethylcellulose; crospovidone; Aerosil; sugar; talc; gelatin; titanium dioxide; acacia; silver foil; softened water; methyl parahydroxybenzoate; propyl parahydroxybenzoate |
10 pcs in blister; There are 10 blisters in a box.
Sex therapist Vladimir Panin
The drug has a positive effect on the reproductive system
Hello! In my opinion, Tentex Forte is a high-quality nutritional supplement. Tentex Forte in a short time allows a man to get rid of many problems in the sexual sphere of life:
| restore | physical activity |
| eliminate | symptoms of erectile dysfunction |
| enhance | potency in older people |
The combined formula of the drug includes a number of herbal substances that allow you to achieve the above results by influencing the state of the spinal centers of activity, namely:
- parts of the spinal cord;
- parts of the diencephalon;
- central nervous system.
Treatment with Tentex Forte gives noticeable results only after a course of treatment lasting from 40 to 60 days.
Casanova set from 899 rub.
Lovelace set from 899 rub.
Family set from 1199 rub.
How to choose a drug to increase potency
Directions for use and doses
Inside
with a small amount of milk or tea.
For functional disorders occurring with weak erections: 2 tables. in the morning and 2 tablets. in the evening half an hour to an hour before bedtime.
To restore sexual activity after previous somatic diseases: 2 tables. 2 times a day for 3-4 weeks, then as needed.
For weak sexual activity in older people: 2 tablets. 2 times a day for 45–50 days; the course is repeated every 6 months.
Buy Ripart Forte synovial fluid prosthesis 15 mg/ml 3 ml No. 1 in pharmacies
product name
“Medicine for replacing synovial fluid RIPART®, volumes 1 ml, 2 ml, 3 ml, RIPART® Forte, volumes 1 ml, 2 ml, 3 ml and RIPART® Long, volumes 1 ml, 2 ml, 3 ml” (hereinafter referred to as text - Means for replacing synovial fluid).
Type of contact with the human body: constant contact with the internal environment of the body.
This product is sterile. For single use.
Conditions of use: in clinics, hospitals and other medical institutions by qualified medical personnel trained in the technique of injecting synovial fluid replacement agents.
Application area
The product is used for administration to replace synovial fluid in case of joint damage, to eliminate pain and improve joint mobility. The agent for replacing synovial fluid is used for osteoarthritis and other degenerative-dystrophic, traumatic and post-traumatic changes in the joints: knee, hip and other large joints, as well as as an aid in orthopedic surgery.
The medical device is used in traumatology, orthopedics, and sports medicine.
Product characteristics
The synovial fluid replacement product is a sterile, colorless and transparent viscous solution of highly purified sodium hyaluronate, obtained by biofermentation. The product contains sodium hyaluronate in a concentration of 10 mg/ml (RIPART® synovial fluid replacement agent), 15 mg/ml (RIPART® Forte synovial fluid replacement agent) and 20 mg/ml (RIPART® Long synovial fluid replacement agent), sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride 0.9% solution for infusion.
Sodium hyaluronate is the sodium salt of hyaluronic acid, a glycosaminoglycan formed by groups representing D-glucuronic acid and N-acetyl-D-glucosaminodisaccharide. It is widely present in the extracellular matrix in both animals and humans. The molecular weight of sodium hyaluronate used in the manufacture of the synovial fluid replacement agent must be at least 3 MDa.
Sodium hyaluronate belongs to a small group of substances that are the same for all living organisms. Sodium hyaluronate is a natural polysaccharide that is part of all tissues of the body, and sodium hyaluronate is found in especially high concentrations in synovial fluid and skin. The synovial fluid replacement agent consists of biosynthetically produced and purified sodium hyaluronate. Sodium hyaluronate in the body is a natural component of synovial fluid, which in joints serves as a lubricant for cartilage and ligaments, and is also an shock absorber. It is known that synovial fluid in affected joints has lower viscosity and elasticity than synovial fluid in healthy joints. Injecting sodium hyaluronate into a joint to restore viscosity and elasticity can reduce pain and restore joint mobility.
The composition of the synovial fluid replacement agent ensures the restoration of viscoelastic properties and the transition of the viscous properties of the solution into elastic (elastic) in the range of shear rates from 0.5 to 2.5 Hz, which corresponds to the range of movements from walking to running.
Main technical characteristics and materials used in manufacturing
Table 1. Main technical characteristics of the product
| Index | Values | |
| 1 | Chroma | Colorless |
| 2 | Transparency | Transparent |
| 3 | Overall length (pre-filled syringe with piston), mm (± 1%) | 117 (for a syringe with a volume of 1 ml) 135 (for a 2ml syringe) 153 (for a 3ml syringe) |
| 4 | Weight of the product in individual packaging (in a syringe), g (± 10%) | 12.0 (for a syringe with a volume of 1 ml) 13.1 (for a 2ml syringe) 14.2 (for a syringe with a volume of 3 ml) |
Table 2 - Materials used in the manufacture of the product
| Product part name | Material |
| Synovial fluid replacement agent | One milliliter contains: Sodium hyaluronate 10/15/20 mg Sodium dihydrogen phosphate 0.1 mg Disodium hydrogen phosphate 0.6 mg Sodium chloride, solution for infusion 0.9% – up to a volume of 1 ml |
| Syringe: | |
| Cylinder | Borosilicate glass Type 1 |
| Cap | Elastomer BDM-PS |
| Syringe rod | Elastomer BDM-PS |
| Piston seal | Elastomer BDM-PS |
| Finger rests | Elastomer BDM-PS |
| Package | |
| Individual packing | Paper, polymer film |
| Cardboard pack | Cardboard |
Information about the presence of a medicinal product, materials of animal and (or) human origin in a medical product
The synovial fluid replacement product contains the following drugs:
- sodium hyaluronate; - sodium chloride, solution for infusion 0.9%;
Materials of animal and (or) human origin are not contained in this medical product.
Sterility
The product is supplied sterile. Sterilization parameters: steam sterilization method in accordance with the requirements of GOST R ISO 17665-1.
Repeated sterilization of the product is prohibited. Reuse is prohibited.
Indications, contraindications, warnings, precautions, side effects
Indications for use:
— Osteoarthritis and other degenerative-dystrophic, traumatic and post-traumatic changes in joints: knee, hip and other joints. — As an aid in orthopedic surgery. — For use in patients who have increased physical activity and regularly load the damaged joint.
Contraindications:
— Do not use in patients suffering from hypersensitivity (allergy) to products containing sodium hyaluronate. — It is prohibited to inject the Synovial Fluid Replacement Agent into the joint of patients who have infectious or skin diseases in the area where the injection is intended.
Warnings:
To prepare the skin, it is prohibited to simultaneously use disinfectants containing quaternary ammonium salts, since sodium hyaluronate may form a precipitate in their presence.
Intravascular administration is prohibited due to the possibility of systemic adverse side effects. It is prohibited to use the product to replace synovial fluid during intraocular surgery.
Precautionary measures:
— The safety and effectiveness of injection of this product in parallel with other intra-articular injections have not been studied. — Efficacy has been established only if the minimum recommended course of treatment is followed. — The synovial fluid replacement agent should be used with caution in patients with signs of impaired venous or lymphatic drainage in the lower extremities. — For bilateral treatment, separate syringes should be used for each knee or hip joint. — Local anesthetics should not be used if the patient is known to be allergic or hypersensitive to local anesthetics. — X-ray-guided hip injections should not be performed using radiocontrast agents if the patient is known to be allergic or hypersensitive to radiocontrast agents. — STERILE CONTENTS. The pre-filled syringe is intended for single use. The contents of the syringe must be used immediately after the container is opened. Any unused amount of Synovial Fluid Replacement Agent should be discarded. — It is necessary to check the expiration date and the integrity of the individual packaging (syringe) before using the medical product. Do not use after the expiration date, or if the packaging is open or damaged.
Side effects:
The synovial fluid replacement agent is well tolerated. Possible side effects include short-term pain at the injection site, a feeling of heat, bruising, redness and/or swelling. As a rule, such reactions disappear without a trace within 2-3 days and do not in any way affect the effectiveness of treatment. Cases of allergic and anaphylactic reactions are rare. If precautions are not taken during intra-articular administration, septic arthritis may occur in very rare cases.
Risks of use:
The manufacturer has determined the risks for the patient associated with the occurrence of each type of hazardous factors and the occurrence of their consequences. The parameters for reducing risks when applying measures to prevent the occurrence of conditions for the manifestation of hazardous factors or the occurrence of their consequences are calculated.
It has been established that after the implementation of risk control measures, no new risks arise, and the overall residual risk is considered acceptable; The production risks do not change depending on the composition and type of packaging of a medical product.
Patient Information
- As with any invasive procedures performed on the joints, the patient is advised to avoid any physical exertion, as well as prolonged (lasting for more than 1 hour) activities associated with bearing weight loads (this applies, for example, to jogging and tennis) within 48 hours after intra-articular injection of the product. — The safety and effectiveness of use of the drug for replacing synovial fluid in women during pregnancy and lactation, as well as in children under 18 years of age, has not been established.
Recommendations for a medical specialist
The volume of synovial fluid replacement agent administered depends on the size of the joint. The physician is responsible for determining the applicable volume and must ensure that the joint is not overloaded.
A course of treatment with RIPART® synovial fluid replacement agent usually requires a cycle of procedures consisting of 3-5 injections (with an interval of 1 week).
A course of treatment with RIPART® Forte, a synovial fluid replacement agent, usually requires a cycle of procedures consisting of 1-3 injections (with an interval of 1 week).
A course of treatment with RIPART® Long, a synovial fluid replacement agent, usually requires a cycle of procedures consisting of 1-2 injections (with an interval of 1 week).
The amount of sodium hyaluronate injected into the joint during the procedure is determined according to tables 3, 4 and 5. The choice of dosage is at the discretion of the attending physician.
Table 3. For RIPART® Synovial Fluid Replacement Agent
| Syringe filling volume (10 mg/ml (1%)) | The amount of sodium hyaluronate in the syringe |
| 1 ml | 10 mg |
| 2 ml | 20 mg |
| 3 ml | 30 mg |
Table 4. For Synovial Fluid Replacement Agent RIPART® Forte
| Filling volume (15 mg/ml (1.5%)) | The amount of sodium hyaluronate in the syringe |
| 1 ml | 15 mg |
| 2 ml | 30 mg |
| 3 ml | 45 mg |
Table 5. For Synovial Fluid Replacement Agent RIPART® Long
| Filling volume (20 mg/ml (2%)) | The amount of sodium hyaluronate in the syringe |
| 1 ml | 20 mg |
| 2 ml | 40 mg |
| 3 ml | 60 mg |
If necessary, the course can be repeated.
The decision on the applicability of a repeated course is made by the attending physician.
Procedure for working with a medical device
1. The synovial fluid replacement agent is administered intra-articularly once. Subcutaneous administration of lidocaine or a similar local anesthetic may be recommended prior to administration of the synovial fluid replacement agent. 2. Do not use Synovial Fluid Replacement Product if the blister pack is opened or shows signs of damage. Do not use the product after the expiration date indicated on the packaging. 3. When preparing for use and during the actual use of a medical device, strict adherence to aseptic rules is required. 4. If necessary (if present), remove joint effusion before administering Synovial Fluid Replacement Agent. 5. It is necessary to remove the screw cap of the syringe and the cap of the needle tip in compliance with all the rules of asepsis. Introduction Means for replacing synovial fluid into the joint must be carried out using an appropriately sized needle (selected based on the size of the joint). The needle is not included in the product packaging.
Inject the required volume of synovial fluid replacement into each joint. If there is a doctor's order that involves injection into several joints, a separate syringe must be used for each joint.
The synovial fluid replacement product is a DISPOSABLE MEDICAL DEVICE (REPEATED USE IS PROHIBITED).
Conditions of use, storage and transportation
The medical device is used indoors at an ambient temperature of 2°C to 25°C.
Transportation must be carried out by all types of transport, in closed vehicles, in accordance with the rules for the carriage of goods in force for this type of transport.
The synovial fluid replacement agent must be transported in the manufacturer's packaging at a temperature of 2°C to 25°C and a relative humidity of 30 to 75% without moisture condensation.
The synovial fluid replacement product must be stored in the manufacturer's packaging, protected from direct sunlight, heat and freezing, at a temperature from 2°C to 25°C and relative humidity from 30 to 75% without moisture condensation.
Biodegradation of a medical device in the patient’s body
The protective film formed after the introduction of the synovial fluid replacement agent retains its elastic properties for 6 months.
After 6 months, the synovial fluid replacement agent breaks down under the influence of a group of tissue enzymes called hyaluronidases into decomposition products: oligosaccharides and low molecular weight hyaluronates, which are subsequently excreted from the body through natural metabolic pathways.
Removal or replacement Synovial fluid replacement agents are not possible because it is inseparably mixed with the synovial fluid of the joint.
Medical product packaging
The synovial fluid replacement product is individually packaged as a syringe. Next, 1 syringe is packaged in a single-barrier polymer contour cell packaging, hermetically sealed with laminated paper or multilayer combined paper-based material. Next, single-barrier polymer contour blister packaging 1 pc. Packed in a cardboard box. Instructions for use included 1 piece.
Disposal Information
The medical device must be disposed of after use or expiration date, as well as if the integrity of the packaging is damaged, in accordance with the local legislation of the consumer’s country.
Disposal of used syringes must be carried out in accordance with SanPiN 2.1.7.2790-10 for class B waste (epidemiologically hazardous waste).
Unused medical products with an expired expiration date or with damaged packaging, as well as blister packaging, cardboard packs and shipping containers are disposed of in accordance with SanPiN 2.1.7.2790-10 for class A waste (epidemiologically safe waste, similar in composition to solid household waste) .
Guarantees
The manufacturer guarantees that the quality of the product meets the requirements of the technical specifications, subject to the conditions of use, integrity of packaging, transportation and storage conditions in accordance with the manufacturer’s instructions for use.
The warranty period when stored in packaging is 3 years from the date of production (packaging).
After the warranty period expires, the product must be disposed of.
